Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

被引：0

作者：

Leslie, K. K. ^{[1
,2
,3
,4
,5
,6
,7
]}

Sill, M. W. ^{[1
,2
,3
,4
,5
,6
,7
]}

Darcy, K. M. ^{[1
,2
,3
,4
,5
,6
,7
]}

Baron, A. T. ^{[1
,2
,3
,4
,5
,6
,7
]}

Wilken, J. A. ^{[1
,2
,3
,4
,5
,6
,7
]}

Godwin, A. K. ^{[1
,2
,3
,4
,5
,6
,7
]}

Cook, L. ^{[1
,2
,3
,4
,5
,6
,7
]}

Schilder, R. J. ^{[1
,2
,3
,4
,5
,6
,7
]}

Schilder, J. M. ^{[1
,2
,3
,4
,5
,6
,7
]}

Maihle, N. J. ^{[1
,2
,3
,4
,5
,6
,7
]}

机构：

[1] Univ New Mexico, Albuquerque, NM 87131 USA

[2] Univ Iowa, Albuquerque, NM USA

[3] Gynecol Oncol Grp, Stat Off, Buffalo, NY USA

[4] Univ Kentucky, Lexington, KY USA

[5] Yale Univ, New Haven, CT USA

[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[7] Indiana Univ, Bloomington, IN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16542

引用

页数：2

共 50 条

[41] Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study
Santin, Alessandro D.
GYNECOLOGIC ONCOLOGY, 2010, 118 (01) : 95 - 96
[42] Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer - A Gynecologic Oncology Group study
Plaxe, SC
Blessing, JA
Morgan, MA
Carlson, J
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (01): : 45 - 47
[43] Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study
Plaxe, SC
Blessing, JA
Bookman, MA
Creasman, WT
GYNECOLOGIC ONCOLOGY, 2002, 84 (01) : 32 - 35
[44] PHASE-II TRIAL OF CISPLATIN IN ADVANCED OR RECURRENT CANCER OF THE VAGINA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
THIGPEN, JT
BLESSING, JA
HOMESLEY, HD
BEREK, JS
CREASMAN, WT
GYNECOLOGIC ONCOLOGY, 1986, 23 (01) : 101 - 104
[45] Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase II Trial in women with recurrent or persistent carcinosarcomas of the uterus
Huh, Warner K.
Sill, Michael W.
Darcy, Kathleen M.
Elias, Kevin M.
Hoffman, James S.
Boggess, John F.
Alvarez, Ronald D.
Long, Harry J.
O'Malley, David M.
Birrer, Michael J.
GYNECOLOGIC ONCOLOGY, 2010, 117 (02) : 248 - 254
[46] Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group
Miller, David Scott
Blessing, John A.
Ramondetta, Lois M.
Pham, Huyen Q.
Tewari, Krishnansu S.
Landrum, Lisa M.
Brown, Jubilee
Mannel, Robert S.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2744 - +
[47] Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
Santin, A.
Patricia, G.
Sill, M.
McMeekin, D.
Leitao, M.
Brown, J.
Sutton, G.
Van Le, L.
Boardman, C.
GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S18 - S18
[48] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study.
Burger, RA
Sill, M
Monk, BJ
Greer, B
Sorosky, J
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 457S - 457S
[49] A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study
McMeekin, D. Scott
Sill, Michael W.
Benbrook, Doris
Darcy, Kathleen M.
Stearns-Kurosawa, Deborah J.
Eaton, Lynne
Yamada, S. Diane
GYNECOLOGIC ONCOLOGY, 2007, 105 (02) : 508 - 516
[50] Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: A gynecologic oncology group study
Muggia, FM
Blessing, JA
Sorosky, J
Reid, GC
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) : 2360 - 2364

← 1 2 3 4 5 →